<table id="table5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5: Drug Interactions: Pharmacokinetic Parameters for Etravirine in the Presence of Co-administered Drugs</caption>
<col align="left" span="1" valign="top" width="17%"></col>
<col align="center" span="1" valign="top" width="17%"></col>
<col align="center" span="1" valign="top" width="10%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<tbody>
<tr>
<th colspan="1">Co-administered Drug</th>
<th colspan="1">Dose/Schedule of Co-administered Drug</th>
<th colspan="1">N</th>
<th colspan="1">Exposure</th>
<th colspan="3">Mean Ratio of <content stylecode="underline">Etravirine</content>
<br/>Pharmacokinetic Parameters<br/>90% CI; No Effect = 1.00</th>
</tr>
<tr>
<th colspan="1">C<sub>max</sub>
</th>
<th colspan="1">AUC</th>
<th colspan="1">C<sub>min</sub>
</th>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With HIV Protease Inhibitors (PIs)</content>
</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>400 mg q.d.</td>
<td>14</td>
<td>↑</td>
<td>1.47<br/> (1.36–1.59)</td>
<td>1.50<br/> (1.41–1.59)</td>
<td>1.58<br/> (1.46–1.70)</td>
</tr>
<tr>
<td>Atazanavir/<br/> ritonavir<linkhtml href="#footnote-1">*</linkhtml>
</td>
<td>300/100 mg q.d.</td>
<td>14</td>
<td>↑</td>
<td>1.30<br/> (1.17–1.44)</td>
<td>1.30<br/> (1.18–1.44)</td>
<td>1.26<br/> (1.12–1.42)</td>
</tr>
<tr>
<td>Darunavir/<br/> ritonavir</td>
<td>600/100 mg b.i.d.</td>
<td>14</td>
<td>↓</td>
<td>0.68<br/> (0.57–0.82)</td>
<td>0.63<br/> (0.54–0.73)</td>
<td>0.51<br/> (0.44–0.61)</td>
</tr>
<tr>
<td>Lopinavir/<br/> ritonavir<br/>(tablet)</td>
<td>400/100 mg b.i.d.</td>
<td>16</td>
<td>↓</td>
<td>0.70<br/>(0.64–0.78)</td>
<td>0.65<br/>(0.59–0.71)</td>
<td>0.55<br/>(0.49–0.62)</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>600 mg b.i.d.</td>
<td>11</td>
<td>↓</td>
<td>0.68<br/> (0.55–0.85)</td>
<td>0.54<br/> (0.41–0.73)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Saquinavir/<br/> ritonavir<br/>
</td>
<td>1000/100 mg b.i.d.</td>
<td>14</td>
<td>↓</td>
<td>0.63<br/> (0.53–0.75)</td>
<td>0.67<br/> (0.56–0.80)</td>
<td>0.71<br/> (0.58–0.87)</td>
</tr>
<tr>
<td>Tipranavir/<br/> ritonavir</td>
<td>500/200 mg b.i.d.</td>
<td>19</td>
<td>↓</td>
<td>0.29<br/> (0.22–0.40)</td>
<td>0.24<br/> (0.18–0.33)</td>
<td>0.18<br/> (0.13–0.25)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</content>
</td>
</tr>
<tr>
<td>Didanosine</td>
<td>400 mg q.d.</td>
<td>15</td>
<td>↔</td>
<td>1.16<br/> (1.02–1.32)</td>
<td>1.11<br/> (0.99–1.25)</td>
<td>1.05<br/> (0.93–1.18)</td>
</tr>
<tr>
<td>Tenofovir disoproxil fumarate</td>
<td>300 mg q.d.</td>
<td>23</td>
<td>↓</td>
<td>0.81<br/> (0.75–0.88)</td>
<td>0.81<br/> (0.75–0.88)</td>
<td>0.82<br/> (0.73–0.91)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With CCR5 Antagonists</content>
</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>300 mg b.i.d.</td>
<td>14</td>
<td>↔</td>
<td>1.05<br/>(0.95–1.17)</td>
<td>1.06<br/>(0.99–1.14)</td>
<td>1.08<br/>(0.98–1.19)</td>
</tr>
<tr>
<td>Maraviroc (when co-administered with darunavir/ritonavir)<linkhtml href="#footnote-2">†</linkhtml>
</td>
<td>150/600/100 mg b.i.d.</td>
<td>10</td>
<td>↔</td>
<td>1.08<br/>(0.98–1.20)</td>
<td>1.00<br/>(0.86–1.15)</td>
<td>0.81<br/>(0.65–1.01)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With Integrase Strand Transfer Inhibitors</content>
</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>400 mg b.i.d.</td>
<td>19</td>
<td>↔</td>
<td>1.04<br/> (0.97–1.12)</td>
<td>1.10<br/> (1.03–1.16)</td>
<td>1.17<br/> (1.10–1.26)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With Other Drugs</content>
</td>
</tr>
<tr>
<td>Artemether/ lumefantrine</td>
<td>80/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours</td>
<td>14</td>
<td>↔</td>
<td>1.11<br/>(1.06–1.17)</td>
<td>1.10<br/>(1.06–1.15)</td>
<td>1.08<br/>(1.04–1.14)</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>40 mg q.d.</td>
<td>16</td>
<td>↔</td>
<td>0.97<br/> (0.93–1.02)</td>
<td>1.02<br/> (0.97–1.07)</td>
<td>1.10<br/> (1.02–1.19)</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>500 mg b.i.d.</td>
<td>15</td>
<td>↑</td>
<td>1.46<br/> (1.38–1.56)</td>
<td>1.42<br/> (1.34–1.50)</td>
<td>1.46<br/> (1.36–1.58)</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>200 mg q.a.m.</td>
<td>16</td>
<td>↑</td>
<td>1.75<br/>(1.60–1.91)</td>
<td>1.86<br/>(1.73–2.00)</td>
<td>2.09<br/>(1.90–2.31)</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>40 mg q.d.</td>
<td>18</td>
<td>↑</td>
<td>1.17<br/> (0.96–1.43)</td>
<td>1.41<br/> (1.22–1.62)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>20 mg q.d.</td>
<td>16</td>
<td>↔</td>
<td>1.05<br/> (0.96–1.15)</td>
<td>1.01<br/> (0.93–1.10)</td>
<td>1.07<br/> (0.98–1.17)</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>150 mg b.i.d.</td>
<td>18</td>
<td>↓</td>
<td>0.94<br/> (0.75–1.17)</td>
<td>0.86<br/> (0.76–0.97)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Rifabutin</td>
<td>300 mg q.d.</td>
<td>12</td>
<td>↓</td>
<td>0.63<br/> (0.53–0.74)</td>
<td>0.63<br/> (0.54–0.74)</td>
<td>0.65<br/> (0.56–0.74)</td>
</tr>
<tr>
<td>Telaprevir</td>
<td>750 mg every 8 hours</td>
<td>15</td>
<td>↔</td>
<td>0.93<br/>(0.84–1.03)</td>
<td>0.94<br/>(0.85–1.04)</td>
<td>0.97<br/>(0.86–1.10)</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>200 mg b.i.d.</td>
<td>16</td>
<td>↑</td>
<td>1.26<br/>(1.16–1.38)</td>
<td>1.36<br/>(1.25–1.47)</td>
<td>1.52<br/>(1.41–1.64)</td>
</tr>
</tbody>
</table>